These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20191188)

  • 41. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions.
    Van Rappard DC; Mekkes JR
    Br J Dermatol; 2012 Jul; 167(1):206-8. PubMed ID: 22229974
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paradoxical effect of infliximab in a patient with hidradenitis suppurativa.
    Gori A; Rossari S; Bruscino N; Tripo L
    Dermatol Ther; 2012; 25(4):376-8. PubMed ID: 22950564
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say?
    Alhusayen R; Shear NH
    Am J Clin Dermatol; 2012 Oct; 13(5):283-91. PubMed ID: 22676319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 46. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.
    Baerveldt EM; Kappen JH; Thio HB; van Laar JA; van Hagen PM; Prens EP
    Ann Rheum Dis; 2013 Apr; 72(4):626-7. PubMed ID: 23148307
    [No Abstract]   [Full Text] [Related]  

  • 47. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
    Haslund P; Lee RA; Jemec GB
    Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
    Poulin Y
    J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 51. [Fatal pneumococcal sepsis in patient with hidradenitis suppurative treated with infliximab].
    Benítez-Macías JF; García-Gil D; Brun-Romero FM
    Med Clin (Barc); 2008 Dec; 131(20):799. PubMed ID: 19094888
    [No Abstract]   [Full Text] [Related]  

  • 52. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.
    Machet L; Samimi M; Delage M; Paintaud G; Maruani A
    J Am Acad Dermatol; 2013 Oct; 69(4):649-50. PubMed ID: 24034373
    [No Abstract]   [Full Text] [Related]  

  • 53. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
    Theut Riis P; Thorlacius LR; Jemec GB
    Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
    J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.
    van Rappard DC; Limpens J; Mekkes JR
    J Dermatolog Treat; 2013 Oct; 24(5):392-404. PubMed ID: 22397574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biologic therapies for the treatment of hidradenitis suppurativa.
    Rosales Santillan M; Morss PC; Porter ML; Kimball AB
    Expert Opin Biol Ther; 2020 Jun; 20(6):621-633. PubMed ID: 32077334
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comment on "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa".
    Adelman M; Lyons AB; Hamzavi IH
    J Am Acad Dermatol; 2021 Apr; 84(4):e201-e202. PubMed ID: 33253840
    [No Abstract]   [Full Text] [Related]  

  • 59. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 60. Current and emerging nonsurgical treatment options for hidradenitis suppurativa.
    Kerdel FA
    Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S57-9. PubMed ID: 25188460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.